Literature DB >> 31868826

Role of NFATc1 in the Bone-Vascular Axis Calcification Paradox.

Wen Gu, Zhongqun Wang1, Zhen Sun1, Zhengyang Bao1, Lili Zhang1, Yue Geng1, Lele Jing1, Xiang Mao1, Lihua Li.   

Abstract

Nuclear factor of activated T cell cytoplasmic 1 (NFATc1), a crucial member of the transcription factor NFAT family, is indispensable in the immune system and the morphogenesis of cardiac valves and septa and is also vital in osteoclasts and atherosclerotic calcification. Currently, osteoporosis and vascular diseases are severely hazardous to health and quality of life, and the 2 conditions always coincide with each other. The bone-vascular axis calcification paradox serves as a bridge between bone and vascular diseases, linking these 2 seemingly separate diseases, and the receptor activator of NF-κB (RANK)/receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) system may be the common mechanism of the bone-vascular axis calcification paradox. NFATc1 provides a new therapeutic target for bone and vascular diseases. However, the specific mechanism by which NFATc1 acts on the bone-vascular axis calcification paradox, whether NFATc1 is related to the RANK/RANKL/OPG system, and how to use NFATc1 as a therapeutic target to avoid its side effects in other systems requires further study.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31868826     DOI: 10.1097/FJC.0000000000000788

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

1.  Nε-Carboxymethyl-Lysine Mediates Vascular Calcification in Diabetes Caused by Impaired Osteoclastic Resorption Activity Through NFATc1-GNPTAB.

Authors:  Lili Zhang; Zhongqun Wang; Zhen Sun; Mingchang Pang; Chen Shao; Lihua Li
Journal:  J Cardiovasc Transl Res       Date:  2022-08-16       Impact factor: 3.216

2.  Relationship of abdominal aortic calcification with lumbar vertebral volumetric bone mineral density assessed by quantitative computed tomography in maintenance hemodialysis patients.

Authors:  Tian-Yi Chen; Jie Yang; Li Zuo; Ling Wang; Li-Fang Wang
Journal:  Arch Osteoporos       Date:  2022-01-26       Impact factor: 2.617

3.  Aged bone matrix-derived extracellular vesicles as a messenger for calcification paradox.

Authors:  Zhen-Xing Wang; Zhong-Wei Luo; Fu-Xing-Zi Li; Jia Cao; Shan-Shan Rao; Yi-Wei Liu; Yi-Yi Wang; Guo-Qiang Zhu; Jiang-Shan Gong; Jing-Tao Zou; Qiang Wang; Yi-Juan Tan; Yan Zhang; Yin Hu; You-You Li; Hao Yin; Xiao-Kai Wang; Ze-Hui He; Lu Ren; Zheng-Zhao Liu; Xiong-Ke Hu; Ling-Qing Yuan; Ran Xu; Chun-Yuan Chen; Hui Xie
Journal:  Nat Commun       Date:  2022-03-18       Impact factor: 14.919

Review 4.  Vascular Calcification: New Insights Into BMP Type I Receptor A.

Authors:  Zhixing Niu; Guanyue Su; Tiantian Li; Hongchi Yu; Yang Shen; Demao Zhang; Xiaoheng Liu
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

5.  PIAS1 Alleviates Hepatic Ischemia-Reperfusion Injury in Mice through a Mechanism Involving NFATc1 SUMOylation.

Authors:  Jing Luo; Jiequn Li; Ting Li; Zhongqiang Zhang; Guangshun Chen; Qiang Li; Haizhi Qi; Zhongzhou Si
Journal:  Dis Markers       Date:  2022-08-31       Impact factor: 3.464

Review 6.  The effect of long non-coding RNAs in joint destruction of rheumatoid arthritis.

Authors:  Hanxiao Zhao; Li Li; Ning Zhao; Aiping Lu; Cheng Lu; Xiaojuan He
Journal:  Front Cell Dev Biol       Date:  2022-10-03

Review 7.  Effects and mechanisms of natural alkaloids for prevention and treatment of osteoporosis.

Authors:  Bingfeng Lin; Pingcui Xu; Juan Zheng; Xuehui Deng; Qitao Ye; Zhongping Huang; Nani Wang
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

8.  Major vault protein (MVP) negatively regulates osteoclastogenesis via calcineurin-NFATc1 pathway inhibition.

Authors:  Lichan Yuan; Na Zhao; Junyi Wang; Yuying Liu; Li Meng; Shuyu Guo; Erik A C Wiemer; Qi Chen; Yelin Mao; Jingjing Ben; Junqing Ma
Journal:  Theranostics       Date:  2021-05-24       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.